Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Company Overview

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.30 to $7.17
• 52-Week Range: N/A
• Volume: 137,800 shs
• Average Volume: 103,866 shs
• Market Capitalization: $2.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EIGR Stock Analysis - Frequently Asked Questions

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative net margin of 590.80% and a negative trailing twelve-month return on equity of 332.49%.

When did Eiger BioPharmaceuticals' stock split?

Shares of Eiger BioPharmaceuticals reverse split before market open on Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EIGR
• CIK: 1305253
• Web: www.eigerbio.com
• Phone: (650) 272-6138
• Fax: 650-618-1621
• Employees: 56
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($59.1592)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$96.78 million
• Net Margins: -590.80%
• Pretax Margin: -590.79%
• Return on Equity: -332.49%
• Return on Assets: -99.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.31
• Quick Ratio: 3.24

Sales & Book Value

• Annual Sales: $15.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.68 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,480,000
• Free Float: 1,419,000
• Market Cap: $2.55 million
• Optionable: Optionable
• Beta: 1.83